Insights into the oncogenic effects of PIK3CA mutations from the structure of p110α/p85α

Chuan Hsiang Huang, Diana Mandelker, Sandra B. Gabelli, L. Mario Amzel

Research output: Contribution to journalReview articlepeer-review

68 Scopus citations


Phosphatidylinositide-3-kinases (PI3K) initiate a number of signaling pathways by recruiting other kinases, such as Akt, to the plasma membrane. One of the isoforms, PI3Kα, is an oncogene frequently mutated in several cancer types. These mutations increase PI3K kinase activity, leading to increased cell survival, cell motility, cell metabolism and cell cycle progression. The structure of the complex between the catalytic subunit of PI3Kα, p110α, and a portion of its regulatory subunit, p85α reveals that the majority of the oncogenic mutations occur at the interfaces between p110 domains and between p110 and p85 domains. At these positions, mutations disrupt interactions resulting in changes in the kinase domain that may increase enzymatic activity. The structure also suggests that interaction with the membrane is mediated by one of the p85 domains (iSH2). These findings may provide novel structural loci for the design of new anti-cancer drugs.

Original languageEnglish (US)
Pages (from-to)1151-1156
Number of pages6
JournalCell Cycle
Issue number9
StatePublished - May 1 2008


  • Drug design
  • Hot spot
  • PI3K
  • PIK3CA
  • Somatic mutation
  • p110α
  • p110α/p85α

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology
  • Cell Biology


Dive into the research topics of 'Insights into the oncogenic effects of PIK3CA mutations from the structure of p110α/p85α'. Together they form a unique fingerprint.

Cite this